CA2939835C - Aminocarbonylcarbamate compounds - Google Patents

Aminocarbonylcarbamate compounds Download PDF

Info

Publication number
CA2939835C
CA2939835C CA2939835A CA2939835A CA2939835C CA 2939835 C CA2939835 C CA 2939835C CA 2939835 A CA2939835 A CA 2939835A CA 2939835 A CA2939835 A CA 2939835A CA 2939835 C CA2939835 C CA 2939835C
Authority
CA
Canada
Prior art keywords
aminocarbonyl
amino
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2939835A
Other languages
English (en)
French (fr)
Other versions
CA2939835A1 (en
Inventor
Young Soon Kang
Jin Yong Chung
Cheol Young Maeng
Han Ju Yi
Ki Ho Lee
Joon Heo
Eun Hee Chae
Yu Jin Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CA2939835A1 publication Critical patent/CA2939835A1/en
Application granted granted Critical
Publication of CA2939835C publication Critical patent/CA2939835C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/58Y being a hetero atom
    • C07C275/60Y being an oxygen atom, e.g. allophanic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2939835A 2014-02-28 2015-02-27 Aminocarbonylcarbamate compounds Active CA2939835C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946142P 2014-02-28 2014-02-28
US61/946,142 2014-02-28
PCT/KR2015/001915 WO2015130121A1 (en) 2014-02-28 2015-02-27 Aminocarbonylcarbamate compounds

Publications (2)

Publication Number Publication Date
CA2939835A1 CA2939835A1 (en) 2015-09-03
CA2939835C true CA2939835C (en) 2022-11-01

Family

ID=54006446

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2939835A Active CA2939835C (en) 2014-02-28 2015-02-27 Aminocarbonylcarbamate compounds

Country Status (15)

Country Link
US (4) US9403761B2 (https=)
EP (2) EP3587394B1 (https=)
JP (2) JP6452731B2 (https=)
KR (2) KR102487051B1 (https=)
CN (2) CN109627186B (https=)
AR (1) AR099581A1 (https=)
AU (2) AU2015223579B2 (https=)
CA (1) CA2939835C (https=)
CL (1) CL2016002165A1 (https=)
ES (2) ES2759312T3 (https=)
MX (2) MX387796B (https=)
PL (1) PL3110792T3 (https=)
RU (1) RU2688673C2 (https=)
TW (2) TWI698415B (https=)
WO (1) WO2015130121A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888542B2 (en) * 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN111153863A (zh) * 2019-12-13 2020-05-15 浙江工业大学 一种合成动物用抗球虫药物妥曲珠利的方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077289A (en) * 1989-11-30 1991-12-31 Hoechst Roussel Pharmaceuticals Inc. Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
CA2146755A1 (en) * 1992-10-28 1994-05-11 Kenji Takeda Novel 1,2-benzoisoxazole derivative or its salt and brain-protecting agent comprising the same
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP1636188A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Para-substituted phenyl carbamates as inhibitors of hormone sensitive lipase
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US7795307B2 (en) * 2003-10-21 2010-09-14 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
CN101631770A (zh) * 2007-02-02 2010-01-20 科露西德医药品公司 抑制胆碱酯酶的化合物
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8895609B2 (en) * 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102309836B1 (ko) * 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物

Also Published As

Publication number Publication date
RU2688673C2 (ru) 2019-05-22
JP2019059764A (ja) 2019-04-18
EP3110792B1 (en) 2019-09-04
RU2016136193A3 (https=) 2018-10-29
RU2016136193A (ru) 2018-03-30
US9833432B2 (en) 2017-12-05
TW201623224A (zh) 2016-07-01
AU2015223579A1 (en) 2016-08-25
CA2939835A1 (en) 2015-09-03
US20190247356A1 (en) 2019-08-15
JP2017512211A (ja) 2017-05-18
ES2759312T3 (es) 2020-05-08
MX2016010973A (es) 2016-11-29
TWI655179B (zh) 2019-04-01
AR099581A1 (es) 2016-08-03
TWI698415B (zh) 2020-07-11
EP3110792A4 (en) 2017-09-27
CL2016002165A1 (es) 2017-06-09
US20150246874A1 (en) 2015-09-03
MX387796B (es) 2025-03-19
US10485781B2 (en) 2019-11-26
KR20210124520A (ko) 2021-10-14
AU2015223579B2 (en) 2019-06-27
CN106458866A (zh) 2017-02-22
JP6595078B2 (ja) 2019-10-23
CN106458866B (zh) 2018-12-07
US9403761B2 (en) 2016-08-02
RU2019113158A (ru) 2019-06-25
EP3587394B1 (en) 2023-11-01
KR102487051B1 (ko) 2023-01-09
US20180085337A1 (en) 2018-03-29
EP3587394A1 (en) 2020-01-01
WO2015130121A1 (en) 2015-09-03
JP6452731B2 (ja) 2019-01-16
PL3110792T3 (pl) 2020-02-28
CN109627186A (zh) 2019-04-16
AU2019236666A1 (en) 2019-10-17
ES2968840T3 (es) 2024-05-14
US10314808B2 (en) 2019-06-11
MX2020003020A (es) 2021-11-11
KR102309903B1 (ko) 2021-10-06
US20160303067A1 (en) 2016-10-20
KR20160126988A (ko) 2016-11-02
AU2019236666B2 (en) 2021-03-25
EP3110792A1 (en) 2017-01-04
TW201920086A (zh) 2019-06-01
CN109627186B (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
CA2939835C (en) Aminocarbonylcarbamate compounds
JP5868948B2 (ja) リジン特異的脱メチル化酵素1阻害薬およびその使用
US20230218562A1 (en) Aminocarbonylcarbamate compounds
RU2790360C2 (ru) Аминокарбонилкарбаматные соединения
HK40007355A (en) Aminocarbonylcarbamate compounds
HK40007355B (zh) 氨基羰基氨基甲酸酯化合物
HK1233615A1 (en) Aminocarbonylcarbamate compounds
HK1233615B (zh) 氨基羰基氨基甲酸酯化合物
BR112016019737B1 (pt) Composto, e, composição farmacêutica

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202